{"url_path":"/sec/mnpr/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-016982-index.html","accession_number":"0001437749-26-016982","cik":"0001645469","ticker":"MNPR","issuer_name":"Monopar Therapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-016982-index.html","primary_entity_key":"0001645469","primary_entity_name":"Monopar Therapeutics"},"word_count":47,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\nDuring the quarter ended *March 31*, *2026,* no non-employee director or officer of the Company adopted or terminated a “Rule *10b5*-*1* trading arrangement” or “non-Rule *10b5*-*1* trading arrangement,” as each term is defined in Item *408*(a) of Regulation S-K.\n\n \n\n \n\n33\n\n[Table of Contents](#toc)"}